Mural Oncology Cuts 90% of Workforce Following Failed Cancer Immunotherapy Trials
Mural Oncology is discontinuing all clinical development of nemvaleukin alfa after the immunotherapy failed to meet target goals in melanoma and ovarian cancer trials.
Mural Oncology Gears Up for Key Data Readouts of Nemvaleukin in Ovarian Cancer and Melanoma in 2025
Mural Oncology's ARTISTRY-7 trial evaluating nemvaleukin with pembrolizumab in platinum-resistant ovarian cancer has reached 75% of overall survival events.
Nemvaleukin Shows Promising Antitumor Activity in Advanced Solid Tumors
Nemvaleukin, an engineered IL-2 fusion protein, demonstrates tolerability and antitumor activity in the ARTISTRY-1 phase 1/2 trial, both as monotherapy and in combination with pembrolizumab.
Mural Oncology's Nemvaleukin Trials Progressing, Data Readouts Anticipated in 2025
Mural Oncology remains on track with late-stage trials for nemvaleukin alfa, expecting data readouts for platinum-resistant ovarian cancer in late Q1/early Q2 2025.
Mural Oncology Highlights Nemvaleukin Progress and IL-18 Program at Investor Day
Mural Oncology's ARTISTRY-7 trial, evaluating nemvaleukin plus pembrolizumab in platinum-resistant ovarian cancer, anticipates interim data in early Q2 2025.